Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Astellas Launches Dificlir in Europe
June 13, 2012
- Sanofi-Aventis Files NDA for GLP-1 Receptor Agonist Lixisenatide in Japan
June 13, 2012
- Daiichi Sankyo Launches Olmesartan in Mexico
June 12, 2012
- Astellas Completes Enrollment for Global PIII Trial for MDV3100
June 12, 2012
- Sawai Considers Leveraging “MSs with MR Qualifications” with Medipal Group
June 12, 2012
- DSP Aims to Boost Latuda Sales with Add’l Indication of Bipolar Depression in US: President Tada
June 12, 2012
- IPV More Than Double Normal Cost for Japanese Market: Sanofi Pasteur
June 11, 2012
- DSP to Seek Additional Indication of Bipolar Depression for Latuda in US
June 11, 2012
- University of Tokyo Hospital to Take Over Development of Takeda’s AD Treatment Candidate
June 11, 2012
- Ethical Drug Sales Up 7.0% in April: Crecon Report
June 11, 2012
- 2012 MR Trend Survey
June 11, 2012
- Shionogi Aims to Boost ARB Product Lineup with Launch of Combination Drugs
June 8, 2012
- Astellas to Collect Additional Data Comparing Tivozanib with Sunitinib
June 8, 2012
- Tuberculosis Treatment Delamanid Demonstrates 53% Increase in SCC: Otsuka
June 8, 2012
- Prescriptions by Generic Names Further Spreading, Amlodipine Most Frequently Prescribed: Pharmacist Survey
June 7, 2012
- Astellas Initiates PIIb Dose Finding Study for AC220 in Europe and US
June 7, 2012
- DSP, Shionogi to Comarket Combination Drug of Irbesartan, Amlodipine
June 7, 2012
- Novartis Pharma Revises Package Insert for Hypertension Treatment Rasilez
June 7, 2012
- Mr Mark Swindell Appointed Head of Specialty Care: Pfizer Japan
June 7, 2012
- Teva Pharma’s Committee Compiles Report on Issues at Former Taiyo Pharmaceutical Factory
June 6, 2012
ページ
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
As Japan approaches the Fiscal System Council’s “autumn recommendation,” a notable shift is taking shape. The Ministry of Finance (MOF),…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…